MEDINDIA
English
हिन्दी
Español
français
中文
Let's win over COVID-19: Bharat Biotech's intranasal COVID-19 booster vaccine gets Centre's approval.
Intranasal Vaccine to Fight COVID-19
The source said that the nasal vaccine will be used as a heterologous booster among the eligible population. Meanwhile, the intranasal COVID-19 vaccine is also expected to be introduced in the COVID-19 vaccination program, said the source.
Intranasal COVID-19 Vaccine Works Against COVID-19 Variants
Although India has approved intranasal COVID vaccines in recent months, the road to formulating successful intranasal vaccines is not an easy one.
Although India has approved intranasal COVID vaccines in recent months, the road to formulating successful intranasal vaccines is not an easy one.
TOP INSIGHT
Bharat Biotech's intranasal COVID-19 vaccine will be available in the private hospitals for booster dose in the initial phase.
Read More..
Meanwhile, India reported 163 fresh COVID-19 cases along with nine deaths have also been reported in the country. The number of active coronavirus cases declined to 3,380.
Source-IANS
Intranasal COVID Vaccine by Bharat Biotech Proves Safe in Clinical Trials
Bharat Biotech's intranasal vaccine for COVID-19 proves to be safe, effective, well-tolerated, and immunogenic in subjects in controlled clinical trials.
Bharat Biotech's intranasal vaccine for COVID-19 proves to be safe, effective, well-tolerated, and immunogenic in subjects in controlled clinical trials.
Intranasal COVID Vaccine Gets Nod for Phase 2/3 Trials
Bharat Biotech's intranasal vaccine is the first nasal vaccine that has received the regulatory approval for Phase 2/3 trials.
Bharat Biotech's intranasal vaccine is the first nasal vaccine that has received the regulatory approval for Phase 2/3 trials.
Nasal Vaccines Offer the Best Protection Against COVID-19
Immunity against COVID-19 will be possible with a nasal vaccine that leads to mucosal immunity and the development of defence against the SARS-CoV-2 virus.
Immunity against COVID-19 will be possible with a nasal vaccine that leads to mucosal immunity and the development of defence against the SARS-CoV-2 virus.
Email
